What is Lifesci Capital's Forecast for MLYS FY2024 Earnings?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Stock analysts at Lifesci Capital dropped their FY2024 EPS estimates for shares of Mineralys Therapeutics in a note issued to investors on Tuesday, November 12th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earnings of ($3.87) per share for the year, down from their previous estimate of ($3.28). The consensus estimate for Mineralys Therapeutics' current full-year earnings is ($3.08) per share. Lifesci Capital also issued estimates for Mineralys Therapeutics' Q4 2024 earnings at ($1.17) EPS.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings results on Monday, November 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same period in the previous year, the firm earned ($0.57) EPS.

Separately, HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a research report on Tuesday.

Mineralys Therapeutics Price Performance

Mineralys Therapeutics stock traded down $0.09 during midday trading on Thursday, hitting $12.36. 114,354 shares of the stock were exchanged, compared to its average volume of 179,587. Mineralys Therapeutics has a 1 year low of $5.85 and a 1 year high of $16.91. The firm has a market cap of $614.63 million, a P/E ratio of -3.81 and a beta of 1.71. The company has a 50 day moving average price of $12.99 and a two-hundred day moving average price of $12.65.

Institutional Trading of Mineralys Therapeutics

A number of institutional investors have recently made changes to their positions in MLYS. RA Capital Management L.P. lifted its stake in shares of Mineralys Therapeutics by 52.6% in the 1st quarter. RA Capital Management L.P. now owns 4,850,984 shares of the company's stock worth $62,626,000 after acquiring an additional 1,672,508 shares during the period. Affinity Asset Advisors LLC bought a new stake in shares of Mineralys Therapeutics in the 1st quarter worth approximately $4,234,000. SR One Capital Management LP raised its holdings in shares of Mineralys Therapeutics by 12.4% in the 1st quarter. SR One Capital Management LP now owns 2,016,822 shares of the company's stock worth $26,037,000 after purchasing an additional 222,222 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in shares of Mineralys Therapeutics by 60.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 532,506 shares of the company's stock worth $6,230,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Driehaus Capital Management LLC raised its holdings in shares of Mineralys Therapeutics by 40.4% in the 2nd quarter. Driehaus Capital Management LLC now owns 257,371 shares of the company's stock worth $3,011,000 after purchasing an additional 74,074 shares in the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Mineralys Therapeutics

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 25,482 shares of the business's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total transaction of $382,994.46. Following the completion of the transaction, the insider now directly owns 135,974 shares of the company's stock, valued at $2,043,689.22. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Mineralys Therapeutics news, insider David Malcom Rodman sold 25,482 shares of the business's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total transaction of $382,994.46. Following the completion of the transaction, the insider now directly owns 135,974 shares of the company's stock, valued at $2,043,689.22. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Adam Scott Levy sold 10,757 shares of the business's stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $13.57, for a total transaction of $145,972.49. Following the transaction, the chief financial officer now directly owns 236,854 shares of the company's stock, valued at $3,214,108.78. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,510 shares of company stock valued at $735,431. Insiders own 33.24% of the company's stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.